regardless of positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. The insurers are typically building barriers to coverage, including significant price criteria and approval processes that limit patient opportunity. Industry suggest th